Citigroup’s Direxion Daily S&P Biotech Bear 1X Shares LABS Stock Holding History

Citigroup’s Portfolio LABS Stock Details LABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-49,900	Closed	-$1.92M	–	7586
2016 Q4	$1.92M	Buy	+49,900	New	+$1.94M	﹤0.01%	3009

Other funds holding LABS

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citigroup's LABS Position: Q1 2017 in Review

Citigroup sold out of Direxion Daily S&P Biotech Bear 1X Shares (LABS) in Q1 2017, closing a stake of 49,900 shares — an estimated $1.92M sold.

Citigroup first reported a position in LABS in Q4 2016 and held it in 1 quarter. The position peaked at $1.92M in Q4 2016. 2 funds tracked by Wall St. Rank hold LABS as of Q1 2017.

Citigroup reported no remaining Direxion Daily S&P Biotech Bear 1X Shares position as of Q1 2017 after selling out during the quarter.
Citigroup sold 49,900 Direxion Daily S&P Biotech Bear 1X Shares shares in Q1 2017, an estimated $1.92M.
Citigroup first reported a position in Direxion Daily S&P Biotech Bear 1X Shares in Q4 2016 and held it in 1 quarter.
Citigroup's Direxion Daily S&P Biotech Bear 1X Shares position peaked at $1.92M in Q4 2016.
2 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 1X Shares as of Q1 2017.

Based on Citigroup's 13F filing for Q1 2017, filed 12 May 2017.